Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVX836 Phase 2a Influenza Vaccine Study
NCT04192500Phase 2Completed
- Sponsor
- Osivax
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OVX836 in influenza, sponsored by Osivax. Primary endpoint: NP-specific IFNγ T-cell increase measured by ELISPOT at Day 8. Started Dec 2019; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04192500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192500.